Anavex Life Sciences Corp.'s (NASDAQ:AVXL) Shift From Loss To Profit

Simply Wall StFeb 26 06:09 ET

Anavex Life Sciences to Present at the 45th Annual TD Cowen Health Care Conference

GlobeNewswireFeb 24 07:30 ET

Buy Rating for Anavex Life Sciences Due to Solid Financials and European Market Potential

TipRanksFeb 18 06:25 ET · Ratings

Anavex Life Sciences Reports Higher Quarterly Loss Amid R&D Focus

TipRanksFeb 12 22:57 ET

Stocks Trim Losses After Hot Inflation, Bonds Remain Pressured, Tesla Rebounds: What's Driving Markets Wednesday?

BenzingaFeb 12 13:22 ET

Earnings Call Summary | Anavex Life Sciences(AVXL.US) Q1 2025 Earnings Conference

moomoo AIFeb 12 10:04 ET · Conference Call

Anavex Projects EMA Feedback on Alzheimer's Drug by Year-end 2025

Seeking AlphaFeb 12 09:59 ET

Anavex Life Sciences | 10-Q: Q1 2025 Earnings Report

SECFeb 12 09:11 ET · Announcements

Anavex Life Sciences Corp. Reports Q1 Fiscal 2025 Financial Results and Hosts Webcast

Quiver QuantitativeFeb 12 07:41 ET

Anavex Life Sciences Q1 2025 GAAP EPS $(0.14) Beats $(0.19) Estimate, Cash And Cash Equivalents Of $120.8M At December 31, 2024, The Company Anticipates At Current Cash Utilization Rates And Ranges, A Runway Of Approximately 4 Years

BenzingaFeb 12 07:41 ET

Anavex Life Sciences Had Cash and Cash Equivalents of $120.8M at Dec 31 >AVXL

Dow JonesFeb 12 07:31 ET

Anavex Life Sciences 1Q Loss/Shr 14c >AVXL

Dow JonesFeb 12 07:30 ET

Earnings Scheduled For February 12, 2025

BenzingaFeb 12 03:32 ET

Here's the Major Earnings Before the Open Tomorrow

Seeking AlphaFeb 11 18:00 ET

Earnings Preview: AVXL to Report Financial Results Pre-market on February 12

Moomoo NewsFeb 6 20:00 ET

Anavex Life Sciences to Announce Fiscal 2025 First Quarter Financial Results on Wednesday, February 12, 2025

GlobeNewswireFeb 5 07:30 ET

Anavex Life Sciences Price Target Maintained With a $46.00/Share by D. Boral Capital

Dow JonesJan 28 08:04 ET · Ratings

Anavex Life Sciences Is Maintained at Buy by D. Boral Capital

Dow JonesJan 28 08:04 ET · Ratings

Express News | Anavex Life Sciences Announces Issuance of Blarcamesine (Anavex®2-73) Composition of Matter U.S. Patent Expanding Its Intellectual Property Portfolio

ReutersJan 27 07:30 ET

Anavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX2-73) Composition of Matter U.S. Patent Expanding Its Intellectual Property Portfolio

GlobeNewswireJan 27 07:30 ET